03A-1121016
Breast cancer (BC) in East Asia is characterized by remarkably higher and increasing incidence of 10-15 years younger patients, high prevalence in luminal type compared to Western women. An association between young age and significantly increased risk of BC mortality has been reported only among luminal A patients. However, the unknown etiology and molecular mechanisms, high heterogeneity and variable subtype-driven therapeutic outcomes present challenges for BC precision medicine. To address these unmet clinical needs, we established a deep (phospho-) proteomics landscape for BC patients. Our (phospho-) proteomics-informed classification resolved luminal heterogeneity, defined high-risk recurrent early-stage luminal disease, and nominated their biomarkers and actionable druggable pathways. The protein-based classification can be implemented for predicting high-risk luminal subtype patients for early-stage management on precision oncology and intervention treatment plans.
- Our integrated proteomic and phosphoproteomic pipeline achieves high sensitivity and genome-depth for proteomic analysis, which is better than the criteria defined by the US Cancer Moonshot program (>10,000 proteins).
- Proteomic classification system provides new molecular staging to identify high-risk recurrence and worse survival among early stage luminal patients and nominate biomarker candidates for early detection and indication for precision treatment options.
- No other relevant competing technologies and/or commercial products can resolve high-risk luminal disease.
- Early detection of breast cancer.
- Patient stratification for high-risk recurrence assessment of luminal patients.
- Indication for precision treatment options of luminal-subtype.
- Detection Method: Immunohistochemistry staining, mass spectrometry, ELISA.
- Commercial product(s) by IHC kit, ELISA kit, Mass spectrometry assay.
- Specimen: Biopsy, tumor tissue, adjacent normal tissue, liquid biopsy, plasma.
- Used by healthcare providers, hospital and clinics.
Yu-Ju Chen, Sung-Liang Yu, Jyh-Cherng Yu, Yen-Shen Lu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Proteomic Classification for Early Stage Breast Cancer